{"id":3207,"date":"2025-05-23T15:11:37","date_gmt":"2025-05-23T15:11:37","guid":{"rendered":"https:\/\/healthyretirementnews.com\/index.php\/2025\/05\/23\/fda-crackdown-on-off-brand-ozempic-products-set-to-take-effect-threatening-supply-and-access-for-many\/"},"modified":"2025-05-23T15:11:37","modified_gmt":"2025-05-23T15:11:37","slug":"fda-crackdown-on-off-brand-ozempic-products-set-to-take-effect-threatening-supply-and-access-for-many","status":"publish","type":"post","link":"https:\/\/healthyretirementnews.com\/index.php\/2025\/05\/23\/fda-crackdown-on-off-brand-ozempic-products-set-to-take-effect-threatening-supply-and-access-for-many\/","title":{"rendered":"FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many"},"content":{"rendered":"<div data-uri=\"cms.cnn.com\/_components\/action-bar\/instances\/cmawu5req000r26qf3no5abu4@published\" data-label-id-prefix=\"action-bar-start-of-article\" class=\"action-bar\" data-dynamic-breakpoint-placement=\"{&quot;extraLarge&quot;:{&quot;placement&quot;:&quot;.layout-article-elevate__left&quot;}}\" data-expand-conditions=\"{&quot;follow&quot;:{&quot;extraLarge&quot;:{&quot;alwaysExpand&quot;:true}},&quot;shareOptions&quot;:{&quot;large&quot;:{&quot;maxNumOfActions&quot;:1},&quot;medium&quot;:{&quot;maxNumOfActions&quot;:1},&quot;extraLarge&quot;:{&quot;withAction&quot;:&quot;follow&quot;,&quot;maxNumOfActions&quot;:2}}}\">\n<div class=\"action-bar__overlay\"><\/div>\n<div class=\"action-bar__action-sheet\">\n<div class=\"action-bar__action-sheet--header\">\n<div class=\"action-bar__action-sheet--header-title\"><\/div>\n<div class=\"action-bar__action-sheet--header-close\">                            <\/div>\n<\/p>\n<\/div>\n<div class=\"action-bar__action-sheet--action\" data-title=\"follow\">\n<div data-uri=\"cms.cnn.com\/_components\/follow-topics-bar\/instances\/cmawu5rer000v26qf7x1s00ep@published\" data-unauth-redirect=\"\/account\/register\/follow\" data-embed-max-topics=\"\" class=\"follow-topics-bar follow-topics-bar_overlay follow-topics-bar--hide\">\n<div class=\"follow-topics-bar_overlay__inner\">\n<div class=\"follow-topics-bar_overlay__scroll-wrapper\">                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmawu5rer000w26qf1kpa8rfq@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Prescription drugs\" data-id=\"f32c00b3-1166-47be-a590-74882550645e\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Prescription drugs<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmawu5rer000w26qf1kpa8rfq@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Federal agencies\" data-id=\"874fe3a3-ab02-4ed7-8d3b-417b95049613\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Federal agencies<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmawu5rer000w26qf1kpa8rfq@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Retail consumer\" data-id=\"9072f258-97ee-4065-b76a-602c65032c61\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Retail consumer<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>                  <button data-unselectable=\"true\" data-uri=\"cms.cnn.com\/_components\/chip\/instances\/cmawu5rer000w26qf1kpa8rfq@published\" class=\"chip follow-topics-chip \" data-component-variation=\"follow-topics-chip\" data-component-name=\"chip\" data-zjs=\"click\" data-enable-interstitial=\"true\" data-override-success=\"\" data-label=\"Corporate news\" data-id=\"ab583507-95bf-45be-b8c9-592154be4b4a\" data-reset-on-log-out=\"true\">    <span class=\"chip__label\">Corporate news<\/span>    <span class=\"chip__icon\">        <span class=\"chip__icon--check\"><\/span>        <span class=\"chip__icon--add\"><\/span>    <\/span><\/button>        <\/div>\n<div class=\"follow-topics-bar_overlay__fade follow-topics-bar_overlay__fade--hide\"><\/div>\n<p>                      See all topics              <\/p><\/div>\n<\/div>\n<\/div>\n<div class=\"action-bar__action-sheet--action\" data-title=\"share options\">\n<div data-uri=\"cms.cnn.com\/_components\/social-share\/instances\/cmawu5rer000u26qf8qhhdb20@published\" class=\"social-share_labelled-list\">\n<div class=\"social-share_labelled-list__share-links vossi-social-share_labelled-list\" data-type=\"share-links\">        <button class=\"social-share_labelled-list__share\" data-url=\"https:\/\/www.facebook.com\/dialog\/share?app_id=80401312489&amp;href=https%3A%2F%2Fwww.cnn.com%2F2025%2F05%2F21%2Fhealth%2Ffda-compounded-semaglutide-tirzepatide-crackdown&amp;display=popup\" data-type=\"facebook\" aria-label=\"share with facebook\" title=\"Share with Facebook\">                                <span class=\"social-share_labelled-list__share-links--label\">Facebook<\/span>        <\/button>        <button class=\"social-share_labelled-list__share\" data-url=\"https:\/\/twitter.com\/intent\/tweet?text=Check%20out%20this%20article%3A&amp;url=https%3A%2F%2Fwww.cnn.com%2F2025%2F05%2F21%2Fhealth%2Ffda-compounded-semaglutide-tirzepatide-crackdown\" data-type=\"x\" aria-label=\"share with x\" title=\"Share with X\">                                <span class=\"social-share_labelled-list__share-links--label\">Tweet<\/span>        <\/button>                                        <span class=\"social-share_labelled-list__share-links--label\">Email<\/span>                <button class=\"social-share_labelled-list__share\" data-url=\"https:\/\/www.cnn.com\/2025\/05\/21\/health\/fda-compounded-semaglutide-tirzepatide-crackdown\" data-type=\"copy\" aria-label=\"copy link to clipboard\" title=\"Copy link to clipboard\">                                <span class=\"social-share_labelled-list__share-links--label\">Link<\/span>        <\/button>        <\/p>\n<div class=\"social-share_labelled-list__copied\" data-type=\"message\">                        Link Copied!        <\/div>\n<\/p>\n<\/div>\n<p>    <button class=\"social-share_labelled-list__open\" data-type=\"open\" aria-label=\"open social share\" title=\"Open social share\">            <\/button>    <button class=\"social-share_labelled-list__close\" data-type=\"close\" aria-label=\"close social share\" title=\"Close social share\">            <\/button><\/div>\n<\/p>\n<\/div>\n<\/div>\n<div class=\"action-bar__buttons\">            <button class=\"action-bar__button\" data-title=\"follow\">                                        Follow            <\/button>            <button class=\"action-bar__button\" data-title=\"share options\">                                <\/button>    <\/div>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu5rer000t26qf8vyq8ds7@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in the United States have come to rely on.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp00043b6mo99bv165@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Starting in 2022, increased demand led to shortages of semaglutide injections sold by Novo Nordisk under the brand names Ozempic and Wegovy, as well as tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly. Compounding pharmacies were allowed to step in to fill supply gaps while name-brand products were in short supply, selling copycat products that used the same active ingredients but were not approved by the US Food and Drug Administration.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp00053b6mippc33b7@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to stop producing and selling compounded tirzepatide ended in March, and Thursday is the final cutoff date for compounded semaglutide.    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmawuajae000p3b6mc00ba2m3@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/cm1zlbn4m000h65np0tm94fx8@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"20241008-01_Janet McCaskill.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.5625\" data-original-height=\"900\" data-original-width=\"1600\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/20241008-01-janet-mccaskill.jpg?c=original\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">Janet McCaskill and her husband, Barry, at left in November 2022 before starting tirzepatide and at right in November 2023, about a year after Janet started treatment.<\/span>  <\/div><figcaption class=\"image__credit\">Courtesy Janet McCaskill<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">The end of a shortage of popular weight-loss drugs may mean many people lose access to them<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp00063b6mgvw8k8u8@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Thousands \u2013 and perhaps millions \u2013 of patients have been using these compounded GLP-1 receptor agonist medications, which are typically sold at a lower price point than the brand-name products, making them more accessible to many.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawy472r00003b6mzbe85yua@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Michelle Pierce, who gets compounded semaglutide injections from Olympia Pharmaceuticals for help with weight management and high blood sugar, said her insurance denied her requests for GLP-1 medications multiple times before she explored options for compounded products. The effects have been \u201clife\u2013changing,\u201d says the 25-year-old from Texas, and she\u2019s scared to undo progress that has helped her avoid back surgery and get her blood sugar A1C level to the lowest it\u2019s been.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawy996j00053b6me3cwvbcv@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cNow that it\u2019s coming off shortage, I am planning to get off the medication. I don\u2019t really have any other options. I absolutely cannot afford to completely pay out of pocket,\u201d she said.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp00073b6mm6k127d2@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Olympia Pharmaceuticals has been providing vials of compounded GLP-1 drugs for more than 70,000 people each week, said Josh Fritzler, the company\u2019s chief financial officer. GLP-1s accounted for about 40% of the company\u2019s production, and it\u2019s been planning for the stop date since the end of the shortage was announced.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp00083b6mobth6n5g@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cWe sat down and said, \u2018Here\u2019s our goals, here\u2019s how we\u2019re going to process, here\u2019s what we can do to help advocate for patient access, here\u2019s what we can do internally to make sure we have product, and here\u2019s our deadlines,\u2019 \u201d Fritzler said. \u201cWe had to be transparent. \u2026 \u2018OK, we\u2019re going to prioritize the shortage need for the next three months to make sure that we can meet as many patients as possible before this transition is over. Because a lot of them are scared that they\u2019re going to run out.\u2019 \u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp00093b6mr02kgvbu@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Dr. Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School, said she doesn\u2019t support the use of compounded GLP-1 drugs but also worries that restrictions could add new strain to the overall supply.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000a3b6m3n85wowp@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cYou just don\u2019t have that security of [compounded versions] being FDA-regulated. I don\u2019t know what\u2019s in this compound. I don\u2019t know about purity, I don\u2019t know about safety. I don\u2019t know about dosing. I don\u2019t know about drug interactions,\u201d Dushay said. \u201cI really wouldn\u2019t want to be responsible for that.\u201d    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmawubzzg000r3b6m32mfwmos@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/cmao47qba000i27pg0uexex8l@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"GettyImages-2148794361.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.6666666666666666\" data-original-height=\"2000\" data-original-width=\"3000\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/gettyimages-2148794361.jpg?c=original\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">Injections for weight loss. A woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.<\/span>  <\/div><figcaption class=\"image__credit\">Iuliia Burmistrova\/Moment RF\/Getty Images<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">Popular injected weight loss medications work better for one sex. Researchers want to know why<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000b3b6m6ekubwsr@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            But with the new restrictions, she said, she expects that some people who have been relying on compounded products may start to seek out new prescriptions from providers like her \u2013 and that could create a situation similar to when GLP-1 injections first became popular.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawuxcyq00003b6mecwzekzv@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            People who use GLP-1 injections typically start with low doses of the medication and gradually scale up. Compounded versions of the drugs don\u2019t always follow the same standards for efficacy and strength as the branded products, Dushay said, making one-to-one swaps difficult \u2013 so she would assess prescribing needs like new for each patient, no matter what dose of compounded medication they had been using.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000c3b6m2he98yba@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cI would start them over again. I would start them at the starting dose,\u201d Dushay said. \u201cSo the question is: Is there going to be increased pressure on the starting doses of tirzepatide and semaglutide?\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000d3b6md1cc495c@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The restrictions on compounded GLP-1 products come as concerns about existing shortages are bubbling.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawva7z700053b6m6kl01k89@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The FDA declared that shortages of tirzepatide and semaglutide had ended when the drug manufacturers\u2019 \u201cstated product availability and manufacturing capacity can meet the present and projected national demand.\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawvvlxs00093b6mcid9q14e@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cPatients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies,\u201d the agency said when each shortage was declared to be over.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmay5xhtm00003b6m1wjzk6hp@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            A Lilly spokesperson said in a statement that Zepbound and Mounjaro are \u201cfully available\u201d for patients and they \u201cshould not be exposed to untested and unapproved knockoffs.\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmay5zv7800073b6m1mrsfsj5@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cAnyone continuing to sell mass-compounded tirzepatide, including by referring to it as \u2018personalized,\u2019 \u2018tailored\u2019 or something similar, is breaking the law and putting patients at risk,\u201d Lilly\u2019s statement said.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawz1pr600023b6mnrclwivg@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Both Novo Nordisk and Eli Lilly have taken steps to try to lower costs and ease access, such as creating online platforms and offering single-dose vials instead of injector pens.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000e3b6m3fyoipyl@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cI have had direct conversations on behalf of the Outsourcing Facilities Association and provided information to the administration \u2013 both the FDA and HHS \u2013 that shows that I believe that these products \u2013 both GLP-1s \u2013 are still in shortage,\u201d said Lee Rosebush, chairman of the trade association, which represents large-scale compounding pharmacies known as 503Bs. \u201cWhat I\u2019m afraid of happening at the end of this week when the deadline hits is that patients and providers won\u2019t have access to the medications they need, and they will be financially impacted as they move forward because of this.\u201d    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000f3b6mfnjl91cd@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            The Outsourcing Facilities Association filed lawsuits against the FDA about the \u201csudden removal\u201d of tirzepatide and semaglutide from the drug shortage list, but the judge in both cases ruled to allow the FDA plan to block compounded products to continue.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000g3b6mnuvqifl0@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Although health care providers say they have noticed improvements in the availability of GLP-1 drugs since the shortage ended, volatile insurance policies around coverage of the drugs have hampered accessibility.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000h3b6mw11ygpdw@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cThe shortage is much better; insurance coverage is much worse,\u201d said Dr. Disha Narang, an endocrinologist and director of obesity medicine at Endeavor Health. \u201cFrom a practical standpoint, patients are unable to get employer benefits for medication, which now almost upwards of 50% of our country can potentially qualify for. So it\u2019s a very strange time where you\u2019re still trying to justify to insurance companies that obesity is a chronic disease.\u201d    <\/p>\n<div data-uri=\"cms.cnn.com\/_components\/related-content\/instances\/cmawuelj4000z3b6musjqr49v@published\" data-component-name=\"related-content\" class=\"related-content-elevate related-content--article\" data-article-gutter=\"true\">\n<header class=\"related-content__title related-content__title-text\" data-editable=\"content.title\">Related article<\/header>\n<section class=\"related-content__body\">\n<div class=\"related-content__image image__related-content\">\n<div data-uri=\"cms.cnn.com\/_components\/image\/instances\/cm9klstsy001k2cqfhf3b9n0y@published\" class=\"image-elevate image__hide-placeholder\" data-image-variation=\"image\" data-name=\"GettyImages-2092480827.jpg\" data-component-name=\"image\" data-observe-resizes=\"\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--eq-large&quot;: 660}\" data-original-ratio=\"0.6666666666666666\" data-original-height=\"2000\" data-original-width=\"3000\" data-url=\"https:\/\/media.cnn.com\/api\/v1\/images\/stellar\/prod\/gettyimages-2092480827.jpg?c=original\" data-editable=\"settings\">\n<div class=\"image__container \" data-image-variation=\"image\" data-breakpoints=\"{&quot;image--eq-extra-small&quot;: 115, &quot;image--eq-small&quot;: 300, &quot;image--show-credits&quot;: 525}\">           <\/div>\n<div class=\"image__metadata-container media__metadata-container\">\n<div class=\"image__metadata media__metadata\">\n<div class=\"image__caption attribution\">    <span data-editable=\"metaCaption\" class=\"inline-placeholder\">INDIANAPOLIS, INDIANA &#8211; MARCH 17: A flag flies above the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide. (Photo by Scott Olson\/Getty Images)<\/span>  <\/div><figcaption class=\"image__credit\">Scott Olson\/Getty Images<\/figcaption><\/div>\n<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"related-content__headline\">        <span class=\"related-content__headline-text\" data-editable=\"content.headline\">Experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugar, Eli Lilly says<\/span>      <\/p>\n<\/section>\n<\/div>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawy8dvs00023b6mle4jlfva@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            Pierce, who has been using a compounded product, said she has stocked up on six months of supply. But in online community forums she\u2019s a part of, some members are just starting on the compounded drugs without knowing that they could lose access very soon.    <\/p>\n<p class=\"paragraph-elevate inline-placeholder vossi-paragraph\" data-uri=\"cms.cnn.com\/_components\/paragraph\/instances\/cmawu67kp000j3b6mdcelw4xq@published\" data-editable=\"text\" data-component-name=\"paragraph\" data-article-gutter=\"true\">            \u201cI am definitely afraid and will do whatever it takes to try to avoid the fallout,\u201d she said. \u201cBut I don\u2019t really have much control over the situation, unfortunately.\u201d    <\/p>\n<\/p>\n<div>This post appeared first on cnn.com<\/div>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prescription drugs Federal agencies Retail consumer Corporate news See all topics Facebook Tweet Email Link&hellip;<\/p>\n","protected":false},"author":1,"featured_media":3208,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-news"],"_links":{"self":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/posts\/3207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/comments?post=3207"}],"version-history":[{"count":0,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/posts\/3207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/media\/3208"}],"wp:attachment":[{"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/media?parent=3207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/categories?post=3207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthyretirementnews.com\/index.php\/wp-json\/wp\/v2\/tags?post=3207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}